Published Paper Details:

Buccal mucosa is an attractive route for systemic delivery of drugs and it is relatively permeable with a rich blood supply Rabeprazole Sodium is a Proton Pump Inhibitor (PPI). It is mostly prescribed in active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, and erosive esophagitis. Rabeprazole sodium having the highest acid inhibiting effect among other PPI and H2- antagonist. However, Drug having very short half-life (1.5 hr) and low bioavailability (52%). Further, in the marketed formulation various dosage form (granules, tablets and pellets are available) which is enteric coated due to degradation in the gastric and therefore onset of action delayed..In this present study, an attempt has been made to develop a Rabeprazole sodium buccal adhesive tablet to avoid the gastric degradation and first pass metabolism. Two prime considerations in the design of a buccal adhesive tablet. One is to attach firmly to the buccal mucosa and other in case of rabeprazole is the stability of Rabeprazole sodium in human saliva, since it is very unstable in acidic and neutral media. There are various bioadhesive polymer present which are polyacrylic acid derivative such as polycarbophil and other polymer like sodium alginate, Chitosan, HPC, HEC, Sodium CMC, Polyox, HPMC etc. In the Present work, Gantrenz and HPMC selected for the adhesive dosage form. Gantrenz MS 955 is Polyacrylic acid derivative and having both anion and cation.